Compare DexCom, Inc. (DXCM) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $11.26. The key difference: DexCom, Inc. is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | MSTZ | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $89.53 | $27.92 |
52-Week Low | $54.84 | $3.88 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
MSTZ stock trades at $11.40, showing a 5.36% daily gain amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Financial ratios including P/E, P/S, and P/B are unavailable in current data. Recent ETF performance news indirectly references momentum names but lacks direct MSTZ coverage.
The outlook remains cautious with technical indicators favoring bearish momentum. Investment opportunity hinges on fundamental improvements currently obscured by missing financial data. Key risks include continued technical weakness and lack of clear fundamental catalysts. Investors should await earnings clarity for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
